ProCE Banner Activity

NRG1 Oncogenic Gene Fusions Across Solid Tumors: What You Should Know About Testing

Clinical Thought
Read this commentary from Maria E. Arcila, MD, on the recommendations for testing for NRG1 fusions in patients with solid tumors.

Released: November 16, 2021

Expiration: November 15, 2022

Share

Faculty

Maria E. Arcila

Maria E. Arcila, MD

Associate Attending, Pathology
Diagnostic Molecular Service
Pathology Department
Directory, Diagnostic Molecular Pathology Laboratory
Director, Molecular Hematopathology
Diagnostic Molecular Pathology and Hematopathology
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Elevation Oncology

Partners

American Society for Clinical Pathology

ProCE Banner

Faculty Disclosure

Primary Author

Maria E. Arcila, MD

Associate Attending, Pathology
Diagnostic Molecular Service
Pathology Department
Directory, Diagnostic Molecular Pathology Laboratory
Director, Molecular Hematopathology
Diagnostic Molecular Pathology and Hematopathology
Memorial Sloan Kettering Cancer Center
New York, New York

Maria E. Arcila, MD, has disclosed that she has received consulting fees from AstraZeneca, Biocartis, Invivoscribe, and Johnson & Johnson.